Yuan Yuan, Liu Lingxiang, Chen Hu, Wang Yumeng, Xu Yanxun, Mao Huzhang, Li Jun, Mills Gordon B, Shu Yongqian, Li Liang, Liang Han
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China.
Cancer Cell. 2016 May 9;29(5):711-722. doi: 10.1016/j.ccell.2016.04.001.
An individual's sex has been long recognized as a key factor affecting cancer incidence, prognosis, and treatment responses. However, the molecular basis for sex disparities in cancer remains poorly understood. We performed a comprehensive analysis of molecular differences between male and female patients in 13 cancer types of The Cancer Genome Atlas and revealed two sex-effect groups associated with distinct incidence and mortality profiles. One group contains a small number of sex-affected genes, whereas the other shows much more extensive sex-biased molecular signatures. Importantly, 53% of clinically actionable genes (60/114) show sex-biased signatures. Our study provides a systematic molecular-level understanding of sex effects in diverse cancers and suggests a pressing need to develop sex-specific therapeutic strategies in certain cancer types.
长期以来,人们一直认为个体的性别是影响癌症发病率、预后和治疗反应的关键因素。然而,癌症中性别差异的分子基础仍知之甚少。我们对癌症基因组图谱中13种癌症类型的男性和女性患者之间的分子差异进行了全面分析,揭示了与不同发病率和死亡率特征相关的两个性别效应组。一组包含少数受性别影响的基因,而另一组则表现出更为广泛的性别偏向分子特征。重要的是,53%的临床可操作基因(60/114)表现出性别偏向特征。我们的研究提供了对不同癌症中性别效应的系统分子水平理解,并表明迫切需要在某些癌症类型中制定针对性别的治疗策略。